| Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects (NCT02882425) | Actelion | 2015-01-01 |
| Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD (NCT02824653) | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 2015-01-01 |
| To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects (NCT02361034) | Glenmark Pharmaceuticals S.A. | 2015-01-01 |
| A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma (NCT02423343) | Eli Lilly and Company | 2015-01-01 |
| The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy (NCT02467647) | Wuhan University | 2015-01-01 |
| Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002) (NCT02707328) | The Cooper Health System | 2015-01-01 |
| A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women (NCT02364882) | Strategic Science & Technologies, LLC | 2015-01-01 |
| Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia (NCT02982304) | University of British Columbia | 2015-01-01 |
| Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function (NCT02340195) | H. Lundbeck A/S | 2015-01-01 |
| 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies (NCT02348749) | Memorial Sloan Kettering Cancer Center | 2015-01-01 |
| The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using Single-site for Surgical Treatment of Early Gastric Cancer (NCT02347956) | Yonsei University | 2015-01-01 |
| Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia (NCT02407470) | Navy General Hospital, Beijing | 2015-01-01 |
| A Study of LY2835219 in Healthy Participants (NCT02327143) | Eli Lilly and Company | 2015-01-01 |
| A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia (NCT02287233) | AbbVie | 2014-12-31 |
| First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (NCT02339207) | Alios Biopharma Inc. | 2014-12-31 |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia (NCT02316197) | Merck KGaA, Darmstadt, Germany | 2014-12-31 |
| A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects (NCT02294851) | Biogen | 2014-12-31 |
| 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma (NCT02289222) | Ashraf Badros | 2014-12-30 |
| Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 (NCT02333487) | H. Lundbeck A/S | 2014-12-30 |
| A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors (NCT02324257) | Hoffmann-La Roche | 2014-12-30 |
| To Assess the Bioequivalence of Test Oral Formulation of Alpha Lipoic Acid 600 mg HR Film Coated Tablets of Ilko Ilac San. Ve Tic. A.S. Versus Reference Thioctacid (Alpha Lipoic Acid) 600 mg HR Film Coated Tablets of Meda Pharma GmbH& CO .KG, Germany. (NCT04214665) | Ilko Ilac San. ve Tic. A.S. | 2014-12-30 |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression (NCT02325739) | Novartis Pharmaceuticals | 2014-12-29 |
| A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (NCT01823835) | Genentech, Inc. | 2014-12-29 |
| Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (NCT02432274) | Eisai Limited | 2014-12-29 |
| Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma (NCT02180711) | Acerta Pharma BV | 2014-12-29 |
| Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy (NCT02300298) | Boehringer Ingelheim | 2014-12-24 |
| Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment (NCT02161770) | AstraZeneca | 2014-12-22 |
| Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC (NCT02197234) | AstraZeneca | 2014-12-22 |
| Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Adults With Normal Hepatic Function and Adults With Severe Hepatic Impairment (NCT02296853) | Gilead Sciences | 2014-12-22 |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (NCT02296918) | Acerta Pharma BV | 2014-12-22 |
| Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention (NCT02315703) | Janssen Vaccines & Prevention B.V. | 2014-12-22 |
| A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors (NCT02298387) | OncoMed Pharmaceuticals, Inc. | 2014-12-22 |
| Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies (NCT02328014) | Acerta Pharma BV | 2014-12-20 |
| A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults (NCT02298179) | GlaxoSmithKline | 2014-12-19 |
| A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma (NCT02110355) | Kartos Therapeutics, Inc. | 2014-12-19 |
| Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers (NCT02257359) | GlaxoSmithKline | 2014-12-18 |
| A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma (NCT02220842) | Hoffmann-La Roche | 2014-12-18 |
| Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (NCT02188719) | National Institute of Allergy and Infectious Diseases (NIAID) | 2014-12-17 |
| Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS) (NCT01978535) | Mayo Clinic | 2014-12-17 |
| A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (NCT02313077) | Crucell Holland BV | 2014-12-17 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants (NCT02321384) | Hoffmann-La Roche | 2014-12-15 |
| Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose (NCT02157987) | University Hospital, Caen | 2014-12-15 |
| Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder (NCT02350309) | Eisai Inc. | 2014-12-13 |
| Taste Properties of Atazanavir and Cobicistat (NCT02307656) | Bristol-Myers Squibb | 2014-12-12 |
| A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors (NCT02304393) | Hoffmann-La Roche | 2014-12-12 |
| Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI) (NCT02114775) | The University of Texas Medical Branch, Galveston | 2014-12-12 |
| Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors (NCT02533674) | PharmaMar | 2014-12-12 |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612) | National Cancer Institute (NCI) | 2014-12-12 |
| Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA (NCT02270489) | Affiris AG | 2014-12-11 |
| 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS) (NCT02328027) | Advanced Accelerator Applications | 2014-12-11 |
| Clinical Study on Histamine H3 Receptor Occupancy of TS-091 by PET Examination in Healthy Adult Subjects (NCT04631276) | Taisho Pharmaceutical Co., Ltd. | 2014-12-11 |
| Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001) (NCT02341599) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2014-12-11 |
| Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (NCT02101944) | National Cancer Institute (NCI) | 2014-12-09 |
| Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers (NCT02252211) | Ludwig Institute for Cancer Research | 2014-12-09 |
| A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (NCT02252263) | Bristol-Myers Squibb | 2014-12-09 |
| Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer (NCT02250118) | Institut Curie | 2014-12-09 |
| Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 (NCT02211768) | National Cancer Institute (NCI) | 2014-12-08 |
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas (NCT02238496) | Andrew B Lassman, MD | 2014-12-08 |
| Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation (NCT02273739) | Celgene | 2014-12-08 |
| Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) (NCT02315326) | Memorial Sloan Kettering Cancer Center | 2014-12-08 |
| Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors (NCT02255461) | Pediatric Brain Tumor Consortium | 2014-12-08 |
| Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (NCT02333162) | University of Chicago | 2014-12-05 |
| Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) (NCT02314923) | Merck Sharp & Dohme LLC | 2014-12-05 |
| Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (NCT02219789) | Mayo Clinic | 2014-12-05 |
| Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants (NCT02307864) | Janssen Scientific Affairs, LLC | 2014-12-04 |
| Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer (NCT02270606) | Virginia Commonwealth University | 2014-12-04 |
| Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone) (NCT03637361) | Relmada Therapeutics, Inc. | 2014-12-04 |
| Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC (NCT02197247) | AstraZeneca | 2014-12-04 |
| The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects (NCT03462173) | Sunshine Lake Pharma Co., Ltd. | 2014-12-03 |
| A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031) (NCT02212730) | Merck Sharp & Dohme LLC | 2014-12-03 |
| Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study (NCT02303574) | AstraZeneca | 2014-12-03 |
| Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas (NCT02192541) | National Cancer Institute (NCI) | 2014-12-02 |
| Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions (NCT02254447) | GlaxoSmithKline | 2014-12-02 |
| A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone (NCT02730689) | Alvogen Korea | 2014-12-01 |
| MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C (NCT02391038) | Millennium Pharmaceuticals, Inc. | 2014-12-01 |
| A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies (NCT02354417) | Fate Therapeutics | 2014-12-01 |
| Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator (NCT02367053) | Zealand Pharma | 2014-12-01 |
| A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 (NCT02312011) | Ionis Pharmaceuticals, Inc. | 2014-12-01 |
| Effect of Permanent Internal Mammary Artery Occlusion on Extracardiac Coronary Collateral Supply (NCT02475408) | Insel Gruppe AG, University Hospital Bern | 2014-12-01 |
| Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (NCT02202772) | Guarionex J. Decastro | 2014-12-01 |
| Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal (NCT02634515) | Julphar Gulf Pharmaceutical Industries | 2014-12-01 |
| CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (NCT02168907) | Wake Forest University Health Sciences | 2014-12-01 |
| A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics (NCT02286622) | PTC Therapeutics | 2014-12-01 |
| Gender Effects of Dietary Omega-3 Fatty Acids From Plant and Marine Sources on Oxylipins in Healthy Humans (NCT02317588) | University of Manitoba | 2014-12-01 |
| A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers (NCT02516774) | Gustave Roussy, Cancer Campus, Grand Paris | 2014-12-01 |
| Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome (NCT02332655) | Anne Comi, MD | 2014-12-01 |
| Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters (NCT02277171) | Enox Israel Ltd | 2014-12-01 |
| Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461 (NCT02329184) | MyoKardia, Inc. | 2014-12-01 |
| Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003) (NCT02269059) | Merck Sharp & Dohme LLC | 2014-12-01 |
| Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease (NCT02267434) | Affiris AG | 2014-12-01 |
| Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use (NCT02307721) | Norwegian University of Science and Technology | 2014-12-01 |
| Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine (NCT02263248) | Centre for Addiction and Mental Health | 2014-12-01 |
| hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse (NCT02960594) | Inovio Pharmaceuticals | 2014-12-01 |
| Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults (NCT02313155) | Takeda | 2014-12-01 |
| Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia (NCT02221505) | Novartis Pharmaceuticals | 2014-12-01 |
| An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration (NCT02274181) | Repros Therapeutics Inc. | 2014-12-01 |
| A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012) (NCT02320409) | Hutchison Medipharma Limited | 2014-12-01 |
| Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer (NCT02137356) | Sheba Medical Center | 2014-12-01 |
| BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 500mg in Comparison to Each Component Administered Alone (NCT01595880) | LG Life Sciences | 2014-12-01 |
| Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions (NCT02237768) | Pharmaceutical Research Unit, Jordan | 2014-12-01 |